

## Minutes of Implanet's Annual General Meeting held on June 9, 2022

**Bordeaux, Boston, June 10 2022 – 6:00 pm CEST:** IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants, informs its shareholders that its Annual General Meeting was held on Thursday 9 June 2022 at 2:00 pm at the company's registered office in Martillac.

The number of shares held by the shareholders present or represented was 5,305,617, representing a quorum of 26.96%.

All the resolutions of this Annual General Meeting were adopted.

The minutes of the shareholders' meeting will be available within the legal deadlines on the Company's website: [www.implanet-invest.com/general-meeting](http://www.implanet-invest.com/general-meeting)

### Upcoming financial events:

- **H1 2022 revenue**, July 11, 2022, after market
- **H1 2022 results**, September 20, 2022, after market

### About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet's tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 39 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit [www.Implanet.com](http://www.Implanet.com).

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: <http://www.implanet-invest.com/suivi-des-actions-80>

### Contacts

#### IMPLANET

Ludovic Lastennet, CEO  
David Dieumegard, CFO  
Tél. : +33 (0)5 57 99 55 55  
[investors@Implanet.com](mailto:investors@Implanet.com)

#### NewCap

Investor Relations  
Mathilde Bohin  
Nicolas Fossiez  
Tél.: +33 (0)1 44 71 94 94  
[Implanet@newcap.eu](mailto:Implanet@newcap.eu)

#### NewCap

Media Relations  
Arthur Rouillé  
Tél.: +33 (0)1 44 71 94 94  
[Implanet@newcap.eu](mailto:Implanet@newcap.eu)